Keywords: peregrine, initiates, ph, study, tarvacin, vs, hcv
Peregrine initiates Ph I study of Tarvacin vs HCV
Article | 15 August 2005
California, USA-headquartered Peregrine Pharmaceuticals has initiated a Phase I antiviral study of Tarvacin (antiPS/3G4), its first anti-phospholipid therapy candidate. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
